GSK update brings US vaccine exposure into spotlight, as sceptic RFK Jr loomsProactive Investors • 04/25/25
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59Zacks Investment Research • 04/17/25
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's DiseaseGlobeNewsWire • 04/17/25
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization PracticesBusiness Wire • 04/16/25
GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization PracticesBusiness Wire • 04/16/25
GSK in breach for misleading prescribing information on Omjjara, industry body saysReuters • 04/15/25
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change thatProactive Investors • 04/10/25
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkbackCNBC • 04/10/25
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play OutSeeking Alpha • 04/09/25
GSK Awards $2M in Grant Funding for Programs Supporting Adult Vaccination, Commits Additional $2M for 2025Business Wire • 04/09/25
GSK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bronstein, Gewirtz & Grossman, LLC Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 04/08/25
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK Lawsuit - GSKAccesswire • 04/07/25
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GSK plc (GSK) ShareholdersAccesswire • 04/07/25